- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT06343298
Pour évaluer l'innocuité et l'efficacité du MANP chez les sujets souffrant d'hypertension difficile à contrôler/résistante (BOLD-HTN)
Une étude de phase 2 sur la titration de dose en double aveugle, contrôlée par placebo, pour évaluer l'innocuité et l'efficacité du SQ MANP lorsqu'il est administré quotidiennement pendant environ 42 jours chez des sujets souffrant d'hypertension difficile à contrôler/d'hypertension résistante
This is a Phase 2 dose-titration study designed to evaluate the safety and efficacy of MANP subcutaneous injection compared to placebo in reducing baseline daytime systolic blood pressure (SBP), derived from 24-hour ambulatory blood pressure monitoring (ABPM), in subjects with hypertension who are taking 3 or more antihypertensive medications with different mechanisms of action.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Type d'étude
Inscription (Estimé)
Phase
- Phase 2
Contacts et emplacements
Coordonnées de l'étude
- Nom: Seetha R Iyer, MS
- Numéro de téléphone: 212-271-4295
- E-mail: sri@icw.ventures
Sauvegarde des contacts de l'étude
- Nom: Lucia Gonzalez
Lieux d'étude
-
-
Arkansas
-
Little Rock, Arkansas, États-Unis, 72204
- Recrutement
- Lynn Institute of the Ozarks
-
Contact:
- BOLD-HTN
- E-mail: bold-HTN@estar.bio
-
-
California
-
Lake Forest, California, États-Unis, 92630
- Recrutement
- Orange County Research Center
-
Contact:
- BOLD-HTN, BSME
- E-mail: bold-HTN@estar.bio
-
Westlake Village, California, États-Unis, 91361
- Recrutement
- Office of Dr. Edward Portnoy MD
-
Contact:
- BOLD-HTN
- E-mail: bold-HTN@estar.bio
-
-
Florida
-
Daytona Beach, Florida, États-Unis, 32117
- Recrutement
- Arrow Clinical Trials
-
Contact:
- BOLD-HTN
- E-mail: bold-HTN@estar.bio
-
Hollywood, Florida, États-Unis, 33021
- Recrutement
- Royal Research Corp
-
Contact:
- BOLD-HTN
- E-mail: bold-HTN@estar.bio
-
Miami, Florida, États-Unis, 33122
- Recrutement
- Evolution Clinical Trials
-
Contact:
- BOLD-HTN
- E-mail: bold-HTN@estar.bio
-
-
Georgia
-
Acworth, Georgia, États-Unis, 30101
- Recrutement
- Cowry Health
-
Contact:
- BOLD-HTN
- E-mail: bold-HTN@estar.bio
-
Union City, Georgia, États-Unis, 30291
- Recrutement
- SKY CRNG
-
Contact:
- E-mail: boldhtn@estar.bio
-
-
Illinois
-
Chicago, Illinois, États-Unis, 60607
- Recrutement
- Cedar Crosse Research Center
-
Contact:
- BOLD-HTN
- E-mail: bold-HTN@estar.bio
-
-
Michigan
-
Dearborn, Michigan, États-Unis, 48126
- Recrutement
- Revival Research Institute, LLC
-
Contact:
- BOLD-HTN
- E-mail: bold-HTN@estar.bio
-
Flint, Michigan, États-Unis, 48504
- Recrutement
- Aa Mrc Llc
-
Contact:
- Bold-HTN
- E-mail: bold-HTN@estar.bio
-
-
Mississippi
-
Ridgeland, Mississippi, États-Unis, 39157
- Recrutement
- SKY CRNG
-
Contact:
- E-mail: boldhtn@estar.bio
-
-
New York
-
New York, New York, États-Unis, 10029
- Recrutement
- Mt.Sinai
-
Contact:
- E-mail: boldhtn@estar.bio
-
-
North Carolina
-
Monroe, North Carolina, États-Unis, 28112
- Recrutement
- Monroe Biomedical Research
-
Contact:
- BOLD-HTN
- E-mail: bold-HTN@estar.bio
-
-
Texas
-
Coppell, Texas, États-Unis, 75019
- Actif, ne recrute pas
- Prime Research
-
Dallas, Texas, États-Unis, 75230
- Recrutement
- Dallas Renal Group
-
Contact:
- BOLD-HTN
- E-mail: bold-HTN@estar.bio
-
Denton, Texas, États-Unis, 76210
- Recrutement
- Revival Research
-
Contact:
- E-mail: boldhtn@estar.bio
-
Houston, Texas, États-Unis, 77099
- Recrutement
- Pioneer Research Solutions
-
Contact:
- BOLD-HTN
- E-mail: bold-HTN@estar.bio
-
Houston, Texas, États-Unis, 77074
- Recrutement
- Aavon Clinical research
-
Contact:
- E-mail: bold-htn@estar.bio
-
Mansfield, Texas, États-Unis, 76063
- Recrutement
- Prime Clinical Research
-
Contact:
- BOLD-HTN
- E-mail: bold-HTN@estar.bio
-
Plano, Texas, États-Unis, 75075
- Recrutement
- Clinical Investigations of Texas
-
Contact:
- BOLD-HTN
- E-mail: bold-HTN@estar.bio
-
Richmond, Texas, États-Unis, 77407
- Recrutement
- Aavon Clinical Trials
-
Contact:
- BOLD-HTN
- E-mail: bold-HTN@estar.bio
-
Sherman, Texas, États-Unis, 75092
- Recrutement
- Revival Research
-
Contact:
- BOLD-HTN
- E-mail: bold-HTN@estar.bio
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
Subjects will be eligible for enrollment in the study only if they meet ALL the following criteria at time of Screening:
- Male or female subjects aged 18 - 80 years, inclusive, at the screening visit.
- Female subjects must not be of childbearing potential
- Subjects must be taking appropriate doses of 2 or more antihypertensive drugs with different mechanisms of action. One of which must be a diuretic and the other must be an ACEi or ARB at atleast 50% of the maximum recommended dose for hypertension.
- Subjects must have a seated (5 minutes) systolic blood pressure ≥ 140 mmHg and SBP ≥130 mmHg by ABPM prior to randomization (T1).
- Subjects must have a CKD-EPI eGFR ≥ 30 mL/min/1.73m2
- A subset of the subjects with an eGFR between 20-30 ml/min/1.73m2 will be included, not to exceed 10% of the total study subjects.
- Subjects must have a BMI between 18 - 40 kg/m2.
- Subjects who engage in sexual intercourse in which their partner could become pregnant must agree to use a barrier method of birth control (i.e., vaginal/penile condom) with spermicide for the duration of the study and for 90 days after the last dose of study drug or be at least 6 weeks post-vasectomy with confirmation by post-vasectomy semen analysis. In addition, subjects may not donate sperm for the duration of the study and for 90 days after the last dose of study drug.
Exclusion Criteria:
Subjects meeting ANY of the following criteria at time of Screening will be excluded from enrollment:
- Subjects with an average sitting systolic blood pressure ≥180 mmHg or diastolic blood pressure ≥ 110 mmHg at Screening (SV), or prior to randomization at T1.
- Subjects with a history of secondary hypertension, including but not limited to coarctation of the aorta, primary hyperaldosteronism, renal artery stenosis, Cushing's disease, pheochromocytoma, and polycystic kidney disease. If the subject has not previously been evaluated for secondary hypertension, investigators are responsible for evaluating all potential secondary causes of hypertension in accordance with current practices and clinical guidelines before entering the patient into the study.
- Subjects with an HbA1c ≥ 8% at screening (SV)
- Subjects who have experienced myocardial infarction, unstable angina, or a cerebrovascular accident (CVA) within 6 months of the Screening Visit; or sick sinus syndrome or second- or third-degree atrioventricular block, or recurrent atrial tachyarrhythmia, recurrent ventricular tachycardia, or symptomatic bradycardia.
- Subjects who have an implanted cardioverter defibrillator (ICD) that has been fired for any arrhythmia within 3 months of Screening (SV) or implanted pacemakers.
- Subjects with congestive heart failure (New York Heart Association [NYHA] class II-IV)
- Subjects with hemodynamically significant valvular heart disease
- Subjects undergoing hemodialysis or peritoneal dialysis, or history of renal transplant.
- Subjects who have diagnosis or recurrence of malignancy within the past 3 years
- Subjects with a documented history of sleep apnea, with a prescription for CPAP therapy.
- Women of childbearing potential
- Subjects who are pregnant or breastfeeding
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Quadruple
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Comparateur placebo: Placebo-matched control
Placebo-matched vehicle (vehicle minus the active component) |
This is a placebo matched vehicle - Vehicle minus the active ingredient |
|
Comparateur actif: MANP
MANP in vehicle |
MANP (modified atrial natriuretic peptide) is a peptide that is being developed for treatment of difficult to control/resistant hypertension. |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Change from baseline in mean daytime SBP derived from 24-hour ABPM at approximately Day 42.
Délai: Approximately 42 days
|
ABPM |
Approximately 42 days
|
|
Incidence and severity of Adverse events through 4- weeks post end of treatment.
Délai: Approximately 10 weeks
|
Safety |
Approximately 10 weeks
|
|
Incidence and severity of Serious Adverse Events through 4- weeks post end of treatment.
Délai: Approximately 10 weeks
|
Safety |
Approximately 10 weeks
|
|
Incidence and severity of Treatment Emergent Adverse Events through 4- weeks post end of treatment.
Délai: Approximately 10 weeks
|
Safety |
Approximately 10 weeks
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Change in Clinic sitting systolic blood pressure
Délai: Approximately 42 days
|
Achieving mean seated (5 minutes) systolic blood pressure blood pressure control ≤ 130 mmHg at end of treatment visit. |
Approximately 42 days
|
|
Pharmacokinetics - Cmax
Délai: Approximately 42 days
|
Maximum concentration of MANP in plasma post dose on Day 1 and Last day of Treatment |
Approximately 42 days
|
|
Pharmacokinetics - Tmax
Délai: Approximately 42 Days
|
Time required to achieve maximum concentration of MANP in plasma post dose on Day 1 and Last day of Treatment |
Approximately 42 Days
|
|
Anti-drug Antibody
Délai: Approximately 10 weeks
|
Change in Anti-drug antibodies against MANP and ANP at Days 21 and 42 post treatment and at follow up visits 1 and 2 compared to baseline |
Approximately 10 weeks
|
Autres mesures de résultats
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Differential Outcomes in African-American Subject versus Non-African American Subjects
Délai: Approximately 42 days
|
Change mean daytime SBP from ABPM, from baseline compared to end of treatment visit in African American population and the non-African American population at each dose level. |
Approximately 42 days
|
|
Metabolic biomarkers - Glucose
Délai: Approximately 10 weeks
|
Change from baseline in plasma Glucose at end of treatment and Follow-up |
Approximately 10 weeks
|
|
Metabolic biomarkers - Insulin
Délai: Approximately 10 weeks
|
Change from baseline in plasma Insulin at end of treatment and Follow-up |
Approximately 10 weeks
|
|
Metabolic biomarkers - HbA1C
Délai: Approximately 10 weeks
|
Change from baseline in HbA1C at end of treatment and Follow-up |
Approximately 10 weeks
|
|
Lipid biomarkers - HDL
Délai: Approximately 10 weeks
|
Change from baseline in plasma High density Lipoprotein (HDL) at end of treatment and Follow-up |
Approximately 10 weeks
|
|
Lipid biomarkers - LDL
Délai: Approximately 10 weeks
|
Change from baseline in plasma Low density Lipoprotein (LDL) at end of treatment and Follow-up |
Approximately 10 weeks
|
|
Lipid biomarkers - TG
Délai: Approximately 10 weeks
|
Change from baseline in plasma Triglycerides (TG) at end of treatment and Follow-up |
Approximately 10 weeks
|
Collaborateurs et enquêteurs
Parrainer
Les enquêteurs
- Directeur d'études: David Smith, MD, E-Star BioTech, LLC
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Autres numéros d'identification d'étude
- ES_MANP_2001
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Description du régime IPD
All IPD that support publications
Délai de partage IPD
As needed for publication support
Critères d'accès au partage IPD
IPD will be shared with approved collaborators
Type d'informations de prise en charge du partage d'IPD
- PROTOCOLE D'ÉTUDE
- RSE
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .